Thursday, May 14, 2020
The title of this post is the title of this new article from YouGov discussing its survey that provides an interesting window into the positive impression that marijuana reform has made in states that have legalized adult-use. Here are the details:
States that have legalized recreational marijuana don’t seem likely to regret it.
YouGov asked more than 32,000 Americans whether they believe recreational marijuana legislation has been more of a success or failure in the states that have legalized it. In many states where recreational cannabis is legal, a plurality of citizens believes these laws have been more of a success than a failure overall.
That is a particularly strong belief in Colorado, where citizens were among the first-in-the-nation to vote in favor of recreational weed in 2012. Today, about a quarter (26%) of Coloradans say the state-level recreational cannabis laws have been a “success only” and another 45 percent say they have been “more of a success than a failure.” Fewer than one in five (17%) believe the laws have been “more of a failure.”...
While decriminalized marijuana and approvals for medical marijuana became popular in the 1970s and 1990s, recreational marijuana was not legalized anywhere in the United States until 2012. Now, recreational marijuana is legal in 11 states—Washington, Oregon, Nevada, California, Colorado, Michigan, Illinois, Massachusetts, Maine, Alaska, and Vermont—with more states considering the legislation this year.
About two-thirds of those in Oregon (69%) and Massachusetts (67%) believe that the laws have been more of a success. That remains the majority opinion among those who live in Washington (65%), Nevada (64%), California (59%), Illinois (59%), and Michigan (56%).
Michigan and Illinois are the only Midwestern states with legal recreational marijuana, and they are the most recent additions to the list. Michigan became the 10th state to legalize recreational marijuana after residents approved it during the 2018 Midterm elections. Illinois became the 11th after its state government approved recreational cannabis for adults over 21 during the 2019 legislative session. The state began selling recreational marijuana in January.
Maine is the only state surveyed where fewer than half (47%) view the laws as more of a success. About one in nine Mainers say the laws have been a “success only.” About one-third (37%) consider the laws more of a success than a failure. One in five (20%) believe the laws have generally been more of a failure, and one-third (33%) are uncertain.
The folks at YouGov did another interesting poll about marijuana back in April 2020, which is reported here under the headline "Is marijuana essential? Most Americans say yes"
Saturday, May 9, 2020
The title of this post is the title of this notable new article authored by Mitchell Crusto that I just came across and that was recently published in the Spring 2020 issue of the Hastings Constitutional Law Quarterly. Here is its abstract:
There are a growing number of States that have legalized marijuana, challenging the view that marijuana is a dangerous drug. These States are taking positions relative to both the retroactivity of the new laws and to amelioration of past offenses, which arguably contradict United States Supreme Court decisions on the retroactivity of changes in substantive criminal standards. And, many States recognize that past marijuana laws have greatly contributed to the problems related to a broken criminal justice system, including mass incarceration and racial disparities, particularly to the devastation of communities of color.
In response to these legal developments, this Article advances the normative claim that past pot offenders are entitled to retroactive amelioration, in States that have legalized marijuana. This Article argues that such retroactive amelioration has deep support in constitutional provisions and U.S. Supreme Court decisions. Moreover, it suggests that, due to large numbers of offenders, over a long period of time, retroactive amelioration is best achieved through the use of amnesty.
Tuesday, May 5, 2020
The title of this post is the title of this new article authored by Paul J. Larkin, Jr. available via SSRN. Here is its abstract:
The Controlled Substances Act (CSA) prohibits the cultivation and distribution of marijuana by placing it in a category (Schedule I) reserved for drugs that are unhelpful and dangerous. In so doing, the CSA approached this problem from the wrong direction. People use drugs for medical or recreational purposes, and each one requires a separate legal scheme.
Medical Marijuana Use: For more than 50 years, Congress has entrusted to the Commissioner of Food and Drugs the decision whether a particular drug is “safe” and “effective” and therefore can be sold throughout the nation. The reason is that those decisions require the scientific expertise of professionals in the fields of medicine, biochemistry, and the like, not the legal knowledge of Justice Department lawyers or the moral sensibilities of the electorate. Congress should leave to the judgment of the FDA Commissioner the decision how federal law should regulate medical-use marijuana.
Recreational Marijuana Use: American society permits alcohol and tobacco to be sold under regulation. For alcohol, the Twenty-First Amendment empowers states to decide whether and how to sell liquor without much room for supplementary federal regulation. For tobacco, the Family Smoking Prevention and Tobacco Control Act of 2009 authorizes the FDA Commissioner to regulate the distribution of tobacco products. Congress should consider whether to follow the same approach here. There are various factors relevant to that decision. For example, long-term marijuana use can lead some users to become dependent on, or addicted to, the drug, or to suffer serious mental disorders, such as psychosis. Legalizing recreational marijuana use also will increase the number of roadway accidents attributable to cannabis intoxication. Whether the benefits of recreational marijuana use outweigh those harms is the question that Congress should answer.
May 5, 2020 in Business laws and regulatory issues, Federal Marijuana Laws, Policies and Practices, Medical Marijuana Commentary and Debate, Recreational Marijuana Commentary and Debate, Who decides | Permalink | Comments (1)
Friday, May 1, 2020
Though I have been thinking about the question in the title of this post for a few weeks now, this new Marijuana Moment article finally got me to work on this post. The piece is titled "Thousands Of Constituents Urge Governors To Deprioritize Marijuana Enforcement Amid Coronavirus," and here are excerpts:
The marijuana reform group NORML is leading an effort to encourage states to deprioritize the enforcement of cannabis criminalization amid the coronavirus pandemic. So far, more than 4,000 constituents across the country have participated in the organization’s action campaign launched on Wednesday by sending messages to their governors, urging them to take steps to minimize the spread of the virus by avoiding unnecessary marijuana arrests.
NORML created customized email blasts to supporters in all 39 states that have yet to legalize marijuana for adult use. Each one contains a link to a suggested prewritten letter asking the governor to abide by the group’s public health recommendations during the COVID-19 outbreak.
Beyond deprioritizing marijuana enforcement, the organization said states should also drop existing charges for nonviolent cannabis violations “in order to reduce non-essential interactions,” review and release those currently incarcerated for marijuana convictions and waive pending probation requirements for cannabis-related cases.
Though I am unaware of any proclamations that formally call for police and prosecutors to deprioritize marijuana enforcement, it is my sense that functionally a lot of police and other law enforcement are deprioritizing all sorts of low-level criminal enforcement. For example, this local article on plummeting arrest rates notes:
In some places, police leaders have been frank about ordering officers to cease arresting for low-level crimes. In some places, prosecutors are refusing to pursue such cases. For example, Philadelphia police have been ordered to avoid arrests for crimes like drug offenses and burglaries. Instead, they are issuing warrants to be processed once the health crisis abates, according to reporting by the Associated Press.
Similarly, consider this local piece from Indiana: "The sheriff’s office is making fewer arrests to combat the spread of disease, [Jay County Sheriff] Ford said. For those charged with most non-violent misdemeanors and drug-related Level 6 felonies, court summons are being issued instead of them being arrested." And this piece from Austin, Texas with some more specifics: "Austin posted the fewest number of arrests in the month of March for at least four years.... Some of the largest declines include a 75% drop in traffic warrant arrests, to 33 arrests this March from 132 arrests in March 2019. A similar drop was also seen in the number of those arrested and charged with possession of marijuana."
I am not knocking NORML for seeking a formal call for police and prosecutors to deprioritize marijuana enforcement, but I am really interest in seeing whatever data might be available concerning just how much enforcement is currently afoot. My guess is relatively little, though still arguably a lot more than is healthy or just during these weird and uncertain times.
Eventually, but likely at least a few years from now, we will get official FBI arrest data for 2020 and we will all surely see a wide array of notable "COVID" craters. I sure hope someone might be collecting and assessing the marijuana arrest data a lot sooner.
Thursday, April 30, 2020
As a time with no actual sports, it is nice to have a good excuse to check out ESPN's website where one now finds this very lengthy article sharing the title of this post. The lengthy piece is worth reading in full, and here are excerpts (with my emphasis added):
The marijuana stigma that plagued [Ricky] Williams' NFL career is eroding, if not gone entirely from an enforcement standpoint. In January, Illinois became the 11th state to legalize recreational marijuana. Now, of the 123 teams across MLB, the NBA, NHL and NFL, 50 play in states or provinces where recreational marijuana is legal (40.6%). Another 51 teams play in jurisdictions where medical marijuana is legal (41.5%). That's 82% of teams (101 of 123) that are playing in cities where a player can walk down the street, go into a dispensary, and legally purchase either recreational or medicinal marijuana -- just like they were buying a six pack of beer.
The only states in which any of the four major pro league teams play where there are no broad laws legalizing marijuana are Indiana, Georgia, North Carolina, Tennessee, Texas and Wisconsin.
Sports leagues have adapted. Last year, we wrote about the NHL's marijuana approach -- predicated on treatment, not punishment -- which at the time was the most progressive in professional sports. Today? It's actually the norm.
The NFL ratified a new CBA in March with a drug policy quite similar to the NHL model. The NFL significantly raised the threshold for positive tests (from 35 nanograms to 150) and eliminated its previous window of testing, which spanned from April to August to the first two weeks of training camp. In other words, if players want to smoke weed in the offseason, they are free to do so. But most importantly: Players are no longer suspended solely for marijuana. If a player were to test positive, his case is reviewed by a panel of medical experts who determine if the player needs medical treatment. "Certainly, we see that society is changing its views, but views only change because key facts become more and more obvious to the people who make policy," NFLPA executive director DeMaurice Smith said.
MLB and its union negotiated a new drug policy in December 2019 following Tyler Skaggs' death. While the new policy added testing for opioids, fentanyl and cocaine, plus synthetic weed -- with positive tests being referred to a treatment board -- cannabinoids were taken off the league's drugs of abuse list. That wasn't a huge deal for MLB players, who were only previously tested for marijuana if there was "reasonable cause." It was, however, monumental for minor leaguers, who were regularly tested and faced steep fines and suspensions -- including a 50-game ban for a first-time offense, 100 games for a second and a lifetime ban for the third strike. "The way the league had the rules set up, it was ridiculous," said longtime MLBPA agent Joshua Kusnick. "I can't even imagine how many guys' careers were ruined over marijuana. I personally had clients whose careers were derailed because of it. If you were a fringy prospect and you were popped for marijuana, you were released because teams didn't want to deal with it. And if you were released, you couldn't serve your suspension. So who is going to sign you if you had 50 games to wait?"
The NBA's policy has remained the same -- and is now actually the harshest in North American professional sports. A first positive test means a player must enter the marijuana program. The second positive test calls for a $25,000 fine. The third infraction is a five-game suspension, and five more games are added to each ensuing violation (10 games for a fourth positive test, 15 games for a fifth, etc.). However, the NBA does not test players during the offseason, and the union and league agreed to not test players during the league's coronavirus hiatus.
Monday, April 27, 2020
The title of this post is the title of this notable new paper appearing in the May 2020 issue of the International Journal of Drug Policy and authored by Jonathan Caulkins, Bryce Pardo and Beau Kilmer. Here is its abstract:
Drug use is often measured in terms of prevalence, meaning the number of people who used any amount in the last month or year, but measuring the quantity consumed is critical for making informed regulatory decisions and estimating the effects of policy changes. Quantity is the product of frequency (e.g., number of use days in the last month) and intensity (amount consumed per use day). Presently, there is imperfect understanding of the extent to which more frequent users also consume more intensively.
Methods and data
We examine cannabis flower consumption reported in three similar online surveys fielded in times and places where cannabis was and was not legal. These convenience samples returned enough valid responses (n = 2,618) to examine consumption across different frequencies of use via analyses of measures of central tendency, data visualizations, and multivariate regressions. Additional calculations incorporate data from the National Survey on Drug Use and Health.
Respondents who reported using daily (i.e., 30 days in the past month) consumed almost twice as much per day of use on average as did those reporting less than daily. We find only modest increases in intensity among those using less than daily, but then a substantial increase (p< 0.001) for those who use daily. Most respondents report that on heavy or light use days their consumption differs from a typical day of use by a factor of 2 or more, but only about 25% of days were described as heavy or light. We estimate those using cannabis 21+ days a month account for 80% of consumption vs. 71% of the days of use.
Daily cannabis users consume more intensively than others, including near-daily users. When possible, survey questions should move beyond the presence or absence of use and number of days used.
Thursday, April 23, 2020
One final student presentation in my Marijuana Law, Policy & Reform seminar focused on employment law. Here is the student's description of her topic and some background readings she provided:
My presentation will explore how the legislative requirement that employers accommodate versus not accommodate medical marijuana use impacts the facial validity of medical marijuana statutes. In doing so, I will analyze how state disability statutes interact with the federal Controlled Substances Act and the doctrine of preemption. Ultimately, using language that specifically does not require employers to accommodate medical marijuana use best protects the interests of those who require such use by avoiding challenges to the statute’s validity.
For some background reading on anti-discrimination provisions, preemption, and employment, take a look at the links below:
The last of a big group of student presentations in my Marijuana Law, Policy & Reform seminar will focus on "CBD and its efficacy as a sleep aid." Here some background readings he has provided:
- "CBD & Parkinson's Disease"
- "Is CBD legal? Here’s what you need to know, according to science"
- "Cannabidiol can improve complex sleep‐related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series"
- "Is CBD legal in your state? Check this chart to find out"
- "Cannabidiol (CBD) — what we know and what we don’t
- "Every Question You Have About CBD—Answered"
- "The State of Sleep"
- "What to know about sleep deprivation"
- "Prescription sleeping pills: What's right for you?"
- "Are Sleeping Pills Safe?"
- "1 in 3 adults don’t get enough sleep"
FDA Approved MJ derived medicine
Wednesday, April 22, 2020
This will be another exciting week as students in my Marijuana Law, Policy & Reform seminar are finishing up their presentations on research topics of their choice. The fourth presentation slated for this week will focus on how marijuana reforms intersect with gun ownership. Here is the student's description of his topic and some background readings he has provided:
My presentation will focus on the interaction between legal marijuana and gun ownership. I will begin by analyzing federal firearms laws and their practical implementation by the Bureau of Alcohol, Tobacco, and Firearms (ATF). I then look through examples of the conflicts these laws present in states which have legalized marijuana, and how federal laws currently prohibit any individual from exercising both their right to consume marijuana in legal states and their right to own a firearm under the Second Amendment. For some background reading, here are some helpful links:
Paul Barach, Why Can’t Medical Cannabis Patients Own Guns?, PotGuide (Jan. 17, 2020).
Open Letter to All Federal Firearms Licensees, Bureau of Alcohol, Tobacco, Firearms and Explosives (Sept. 21, 2011).
Aimee Green, Medical Marijuana Cardholders Can’t Be Denied Concealed Gun License Solely Because they Use Pot, Oregon Supreme Court Rules, OregonLive (May 19, 2011).
Mike Lowe, Mixed Legality of Marijuana on State, Federal Levels Leaves Gun Owners in Limbo, WGN9 (Jan. 9, 2020).
April 22, 2020 in Assembled readings on specific topics, Criminal justice developments and reforms, Federal Marijuana Laws, Policies and Practices, Medical Marijuana Commentary and Debate, Recreational Marijuana Commentary and Debate | Permalink | Comments (0)
Student presentation on "How Farm Bill's legalization of hemp-derived CBD products could impact federal marijuana reform"
As mentioned before, the semester is winding down and students in my Marijuana Law, Policy & Reform seminar, soldiering on via Zoom, are making presentations on research topics of their choice. The third presentation slated for this week will focus on the the Farm Bill and federal reforms. Here is part of the student's description of the issue and some background readings she has flagged:
My presentation and my paper focus on how the legalization of hemp-derived CBD products, through the Farm Bill, could have an impact on the federal legalization of marijuana. A few sources I used to help with this research are:
Jeff Smith, What marijuana companies can learn from federal legalization of hemp, Marijuana Business Daily (Feb. 27, 2020).
Jeremy Burke & Skye Gould, States where marijuana is legal, Business Insider (Jan. 1, 2020).
Kimberly Holland, CBD v. THC: What's the Difference?, Healthline (May 20, 2019).
U.S. Department of Agriculture, Farm Bill
John Hudak, The Farm Bill, hemp legalization and the status of CBD: An explainer, Brookings Institute (Dec. 14, 2018).
Students in my Marijuana Law, Policy & Reform seminar are continuing to complete their presentations on research topics of their choice, and the second presentation slated for this week will focus on marijuana tax issues. Here is the student's description of his topic and some some "light" reading selected to help set the stage for his presentation.
In my paper, I set out to find a tax scheme that gives greater weight to the public health concerns of legalization while balancing the desire for revenue and fairness. In doing so, I analyze the three primary tax bases that may be chosen by a legislature: (1) Price, (2) Weight, and (3) Potency, pausing a moment to describe just how complex the concept of marijuana "potency" really is. In doing so, I lay out the benefits and disadvantages of each tax base and use Illinois' tax scheme to illustrate these pros and cons. I also consider whether medical marijuana should be taxed on a separate scheme, exempted from tax, or treated the same as product intended for adult use. Finally, I make a case for a hybrid tax base: tax flower and bud by weight, and edibles and concentrates by potency (as measured by THC).
In making my case, I recognize that there is no perfect marijuana tax scheme. The science is too young, marijuana is too complex a substance (both scientifically and by dint of being both "fun" and medicine), and these factors serve to amplify the push-pull between social goals, revenue, simplicity, and fairness inherent in any tax. I have thus included in my proposal a five-year sunset provision that will force legislators to return to the table and incorporate new science (along with the previous five years of data what worked and did not work in the original law) and hopefully produce a better tax scheme.
BOTEC Analysis LLC, Cannabis Potency Tax Feasibility Study (Oct 2019)
BOTEC Analysis Corp., Testing for Psychoactive Agents (Aug 2013)
Tax Foundation, How High Are Recreational Marijuana Taxes in Your State? (Apr 2019)
Pat Oglesby, Laws to Tax Marijuana (How To Tax It) (June 2012)
Tuesday, April 21, 2020
Students in my Marijuana Law, Policy & Reform seminar are finishing up their presentations on research topics of their choice. The first presentation slated for this week will focus on certain arguments made against recreational marijuana reform. Here is the student's description of his topic and some background readings he has provided:
For my project, I examined some of the arguments that opponents of the legalization of recreational marijuana often stress. My research gave particular attention to the external "costs" of the legalization of recreational marijuana. The three arguments that I will be focusing on for class discussion are (1) the cost of car accidents both fatal and non-fatal, (2) the cost of employee productivity, and (3) the cost of high school dropout rate. I will examine these arguments, discuss some of their strengths and weaknesses, and finally talk about how they can be used in inform better policy in the marijuana space.
Here are some useful articles that I used when researching:
Friday, April 17, 2020
Congressional Cannabis Caucus makes bipartisan call for state-legal cannabis businesses to be included in next COVID relief package
As detailed in this letter, a bipartisan group of US representatives are urging House Leadership to include state-legal cannabis businesses in COVID-19 relief efforts. Here are excerpts from the two-page missive addressed to Nancy Pelosi and Kevin McCarthy:
As you draft the next COVID-19 relief bill, we write to ask that you address one of the shortcomings of the CARES Act — the exclusion of state-legal cannabis businesses and their employees. The COVID-19 crisis response demands the full participation of the American people, businesses, and workforce. However, without relief, a very large population is left without the means to execute the required public health measures and continue to provide financially for their families.
The state-legal cannabis industry is a major contributor to the U.S. economy and workforce, employing over 240,000 workers across 33 states and four territories, and generating $1.9 billion in state and local taxes in 2019.1,2 As states respond to the COVID-19 crisis by shuttering businesses to mitigate the virus’ spread, jurisdictions across the country have recognized cannabis businesses as “essential.” Essential businesses, in many places, can operate during the pandemic provided they abide by required public health safety measures. Like other businesses with continued operations, cannabis businesses have met the moment by preserving access to treatment for patients with chronic conditions, donating protective clothing, and manufacturing equipment for medical use. However, unlike other small businesses, cannabis businesses are not eligible for the CARES Act programs.
State-legal cannabis businesses need access to CARES Act programs to ensure they have the financial capacity to undertake the public health and worker-focused measures experts are urging businesses to take. This includes access to and participation in SBA’s loan programs — financial support that is designed to pay workers, group health care benefits, and family or sick leave. Current SBA policies prevent cannabis businesses from accessing the Paycheck Protection Program (PPP), Emergency Economic Injury Disaster Loans (EIDLs), EIDL grants, or SBA loan forgiveness – programs intended to help businesses fight COVID-19 in safe and equitable ways....
Given the nature of the epidemic, we must ensure that everyone has the capacity to carry out the recommended public health and worker-focused measures. Without doing that, we risk undercutting the public health efforts nationwide. We ask that House leadership include provisions to allow state-legal cannabis businesses and the businesses who work with this industry to access the critical support they need during this unprecedented time.
Thursday, April 16, 2020
With the semester winding down, numerous students in my Marijuana Law, Policy & Reform seminar are scheduled for presentations on research topics of their choice this week. The fourth presentation slated for this week will focus on the transportation of cannabis. Here is part of the student's description of the issue and some background readings he has flagged:
For all the discussion that has been had about the legalization of marijuana, we have not sufficiently discussed how these products should be moved around. The goal of my presentation is to explore this issue by looking at cases that have unfolded and the policies of institutional players. For some background, please see:
April 16, 2020 in Assembled readings on specific topics, Business laws and regulatory issues, Medical Marijuana Commentary and Debate, Recreational Marijuana Commentary and Debate | Permalink | Comments (0)
Wednesday, April 15, 2020
As students "take over" my Marijuana Law, Policy & Reform seminar through presentations on research topics of their choice, I continue to enjoy hearing about (and posting here about) their selected topics. The third presentation slated for this week will focus on marijuana stocks. Here is part of the student's description of the issue and some background readings he has flagged:
While the market for investors is nearly impossible to predict, as the Covid-19 pandemic is currently demonstrating, certain industries seem to be “recession proof” and are viewed as “safer” investments. One such industry is the “sin” industry. Stocks that fall under this category include tobacco, alcohol, weapons, gambling, sex, and most importantly, marijuana. While many of these industries have been publicly traded on major US stock exchanges for decades, the first marijuana stock was not traded until February 27, 2018. Thus, the industry is still in its infancy with many questions left unanswered. I will focus on three areas of law impacting marijuana stocks: 1) the Controlled Substance Act, 2) taxes, and 3) fraud. Further, the history of marijuana stocks in the US, the potential outlook for marijuana stocks in the future, and my opinion on which marijuana stock will be the most successful will be discussed.
Fabian Gorsler, A Marijuana Company is Listed on the U.S. Stock Exchange for the First Time, Highsnobiety (Feb. 27, 2018).
Casey W. Baker, Marijuana’s Continuing Illegality and Investors’ Securities Fraud Problem: The Doctrines of Unclean Hands and IN PARI Delicto, 12 J. Bus. Entrepreneurship & L. 93 (2019).
Erin Fuchs, The Legal Risk of Investing in Weed is ‘Remote’ and ‘Theoretical’, Yahoo Finance (Nov. 3, 2018).
April 15, 2020 in Assembled readings on specific topics, Business laws and regulatory issues, Federal Marijuana Laws, Policies and Practices, History of Marijuana Laws in the United States, Recreational Marijuana Commentary and Debate, Taxation information and issues | Permalink | Comments (0)
Continuing to provide in this space background on from students who are "taking over" Marijuana Law, Policy & Reform seminar through presentations on research topics of their choice, the second presentation this week will focus on employment law issues. Here is how the student working on this topic describes her plans along with background readings she has provided:
While marijuana is legal in some form in thirty-three states, it does not mean that any citizen of those states is immune to negative repercussions for their legal consumption. Even where medical marijuana is legal, not every state guarantees legal protections. My presentation will center on the current state of consumer rights, specifically in the realm of employment. Just as states vary on legalization, few states agree on how marijuana consumption should be treated in an employment context. Many states are hesitant to require an employer to change its hiring or drug-enforcement policies, despite the change in marijuana law. Other states provide employment protections by forbidding an employer from retaliating against an employee for any legal activity performed outside work so long as it does not affect the employee’s ability to perform, without regard to marijuana specifically. I will explore the current trends in employee protections as marijuana law gradually becomes more robust and organized.
The Sham Of Drug Testing For Benefits: Walker, Scott And Political Pandering (old, but still very good)
Tuesday, April 14, 2020
Students in my Marijuana Law, Policy & Reform seminar continue "taking over" through presentations on research topics of their choice, and I will continue providing in this space background on their topics and links to relevant materials they provide. The first presentation this week will focus on the country to the north, and here is how the students working on this big topic describes their plans along with background readings they have provided:
The presentation will focus on medical marijuana in Canada. Like with the United States, the national attitude towards medical marijuana in Canada has evolved over the years. It was only four short years after California effectively legalized medical marijuana in 1996, that a Canadian court ruled Canadians had a right to use medical marijuana. It took almost two decades after that court ruling for marijuana to be fully legalized in Canada. Because marijuana is legal in Canada, there is much that can be learned from research conducted in the country. Research on illegal drugs is often met with push back from the government. Full legalization has opened the door for all aspects of research into the effectiveness of marijuana for treating all kinds of illnesses. This research is necessary to facilitate a better understanding of marijuana and it benefits world-wide.
Government of Canada, "For people registered or designated to produce cannabis for medical purposes"
Government of Canada, "Information for Health Care Professionals: Cannabis (marihuana, marijuana) and the cannabinoids"
Thursday, April 9, 2020
For my paper, I'll be looking at the regulatory frameworks states have developed for edibles. After some background on edibles and their significance to the marijuana industry, I'll discuss the varying levels regulations that states have employed. Then I discuss the three major types of regulations for edibles: (1) testing; (2) packaging and labeling; and (3) THC content. Finally, I conclude by assessing the effectiveness of each type and making my own recommendations for moving forward.
For background, please see the resources below:
Alice G. Walton, Is Eating Marijuana Really Riskier than Smoking It?, FORBES (June 4, 2014).
Jeff Rossen & Jovanna Billington, Rossen Reports Update: Edible Marijuana That Looks Like Candy Is Sending Kids to the ER, TODAY (Sept. 16, 2017).
Robert J. MacCoun & Michelle M. Mello, Half-Baked--The Retail Promotion of Marijuana Edibles, 372 NEW ENG. J. MED. 989 (2015).
Mike Montgomery, Edibles Are the Next Big Thing for Pot Entrepreneurs, FORBES (July 19, 2017).
Ryan Vandrey et al., Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products, 313 JAMA 2491-93 (2015).
Daniel G. Barrus et al., Tasty THC: Promises and Challenges of Cannabis Edibles, RTI PRESS 6 (Nov. 2016).
April 9, 2020 in Assembled readings on specific topics, Business laws and regulatory issues, Medical Marijuana State Laws and Reforms, Recreational Marijuana State Laws and Reforms | Permalink | Comments (0)
Wednesday, April 8, 2020
"Charlotte Figi, 13-year-old Coloradan whose CBD journey inspired medical marijuana reform, dies of COVID-19"
Charlotte Figi, the young Colorado Springs girl whose battle with Dravet syndrome inspired changes to medical marijuana laws, has died of complications from the coronavirus, according to a nonprofit organization co-founded by her mother. She was 13 years old.
Realm of Caring, the nonprofit that focuses on medical cannabis research and education, attributed Figi’s death to “COVID-19 complications” in a Facebook post. A message posted to the Facebook page of Charlotte’s mother, Paige Figi, on behalf of the Figi family says, “Charlotte is no longer suffering. She is seizure-free forever.”
Neither El Paso County nor state health officials have publicly announced the death of a 13-year-old Coloradan due to COVID-19; Charlotte would be the youngest person to date to die in Colorado in connection with the coronavirus.
Charlotte was one of Colorado’s many medical marijuana refugees, whose family moved to the state following the legalization of cannabis. From the time she was an infant, she suffered from frequent and severe seizures because of Dravet syndrome, including many that required hospitalization. But at age 5, Paige Figi gave her cannabidiol, the non-psychoactive compound in cannabis known more commonly as CBD, and Charlotte’s condition changed overnight.
As I mentioned in this recent post, students in my Marijuana Law, Policy & Reform seminar are now "taking over" my class by making presentations on research topics of their choice. The COVID-19 crisis means my resilient students are doing their presenting online, and students are still providing in this space background on their topic and links to some relevant materials before they present. Another coming presentation will focus on sports (remember those?), and here is how my student has described his topic along with background readings he has provided:
For my paper, I will be discussing the intersectionality of Sports and Marijuana. I will primarily focus on athletes, both past and present, being used as a vehicle in leading the charge for reforming marijuana in their respective sports, but also in America. Athletes of past have had influences on a variety of societal issues and inequalities, and I will compare some of the past actions to how athletes of today can affect marijuana. I will also focus on the new agreements in both the MLB and NFL regarding their stance on marijuana, and what impact that will have on the reformation of sports. I will conclude my paper by predicting what the future of sports’ stance will have on the reformation of America. Below are a few links I’ve read over which I will be using in my paper: